Sugi Predict

Sugi Predict / Compounds / SCHEMBL9705671

SCHEMBL9705671

SCHEMBL9705671

C[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 9/20 0.48
▸ REN P00797 4/20 0.48
▸ ACE2 Q9BYF1 3/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ F2 P00734 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ LTA4H P09960 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PEPD P12955 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ HRH1 P35367 1/20 0.45
▸ THPO P40225 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ F2R P25116 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27953019 1.00 ACE (0.48) ACERENACE2KDM4EF2
SCHEMBL9705665 1.00 ACE (0.48) ACERENACE2KDM4EF2
SCHEMBL29666870 0.96 ACE (0.52) ACERENACE2KDM4EF2
SCHEMBL29721089 0.94 CALCRL (0.46) ACEREN
SCHEMBL29666768 0.94 ACE (0.46) ACERENACE2KDM4EF2
SCHEMBL9471485 0.93 ACE (0.48) ACERENACE2KDM4EF2
SCHEMBL29666801 0.93 ACE (0.46) ACERENACE2KDM4EF2
SCHEMBL29666867 0.92 ACE (0.51) ACERENACE2KDM4EF2
SCHEMBL29666873 0.91 ACE (0.44) ACERENACE2KDM4EF2
SCHEMBL29666701 0.90 ACE (0.43) ACERENACE2KDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552831-B2 Saponin purification GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-02-17 — — US disclosed
US-20250360086-A1 ENCAPSULATION METHOD AND PARTICLE UNIV OXFORD INNOVATION LTD (GB) 2025-11-27 — — US disclosed
US-12227540-B2 Saponin purification GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-18 — — US disclosed
EP-4504157-A1 ENCAPSULATION METHOD AND PARTICLE Oxford University Innovation Limited (GB) 2025-02-12 — — EP disclosed
US-20240366745-A1 TROPICAL DISEASE VACCINES MODERNATX, INC. (US) 2024-11-07 — — US disclosed
US-20240293538-A1 NOVEL METHODS FOR MANUFACTURING AN ADJUVANT GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-09-05 — — US disclosed
US-12016919-B2 Methods for manufacturing an adjuvant GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-25 — — US disclosed
US-11951161-B2 Methods for inducing an immune response GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-04-09 — — US disclosed
WO-2023194745-A1 ENCAPSULATION METHOD AND PARTICLE OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-10-12 — — WO disclosed
US-20230272000-A1 SAPONIN PURIFICATION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-08-31 — — US disclosed
US-11679153-B2 Methods for inducing an immune response GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-06-20 — — US disclosed
US-11591364-B2 Saponin purification GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-28 — — US disclosed
US-20220257746-A1 TROPICAL DISEASE VACCINES MODERNATX, INC. (US) 2022-08-18 — — US disclosed
US-20220235095-A1 SAPONIN PURIFICATION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-07-28 — — US disclosed
US-11278611-B2 Zika virus RNA vaccines MODERNATX, INC. (US) 2022-03-22 — — US disclosed
CN-103665170-A Peptide therapeutic conjugates and uses thereof ANGIOCHEM INC 2014-03-26 — — CN disclosed
EP-0209643-B1 PEPTIDE COMPOSITION USEFUL FOR THE MALARIA VACCINE MANUFACTURE AS WELL AS FOR THE PREPARATION OF DIAGNOSTIC KITS FOR THE DETECTION OF MALARIAL DISEASES ENIRICERCHE S.p.A. (IT) 1992-07-08 — — EP disclosed
US-4956449-A Forming polypeptides from tetrapeptides condensed and separated by chromatography ENIRICERCHE, S.P.A. (IT) 1990-09-11 — — US disclosed
EP-0209643-A2 Peptide composition useful for the malaria vaccine manufacture as well as for the preparation of diagnostic kits for the detection of malarial diseases ENIRICERCHE S.p.A. (IT) 1987-01-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11278611-B2 Zika virus RNA vaccines RBM3, NSUN3, RBM12 ACE 524/4885REN 3541/4885ACE2 595/4885
US-11591364-B2 Saponin purification IRF3, STING1, LSS ACE 1766/4885REN 4535/4885ACE2 1077/4885
US-20230272000-A1 SAPONIN PURIFICATION IRF3, STING1, LSS ACE 1766/4885REN 4535/4885ACE2 1077/4885
US-12227540-B2 Saponin purification IRF3, STING1, LSS ACE 1766/4885REN 4535/4885ACE2 1077/4885
US-20220257746-A1 TROPICAL DISEASE VACCINES MTREX, DDX5, DIS3 ACE 514/4885REN 2758/4885ACE2 765/4885
US-20220235095-A1 SAPONIN PURIFICATION STING1, IRF3, LSS ACE 1596/4885REN 4527/4885ACE2 1068/4885
US-20240366745-A1 TROPICAL DISEASE VACCINES MTREX, DDX5, DIS3 ACE 514/4885REN 2758/4885ACE2 765/4885
US-12552831-B2 Saponin purification TLR4, TLR7, TLR3 ACE 4006/4885REN 4713/4885ACE2 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback